Maternal Administration of Probiotics Augments IL17‐Committed γδ T Cells in the Newborn Lung
European Journal of Immunology · 2025
DOI: 10.1002/eji.202451051 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Yohannes Tafesse und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Pharmaceutics, Université Libre de Bruxelles (ULB), Brussels, Belgium. Hauptthemen laut MEDLINE: Probiotics, Receptors, Antigen, T-Cell, gamma-delta, Interleukin-17, Lung. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: WELBIO, Fonds National de la Recherche Scientifique, FNRS-CDR.
Abstract (Originalsprache)
The early life period is increasingly being recognized as a window of opportunity to shape immunity, where microbiota and related probiotics have an important impact. Innate γδ T cells are the first T cells generated in utero, populating epithelial tissues such as the lung and contributing to tissue protection through, for example, IL17 production. Here, we studied the influence of maternal microbiota and probiotic supplementation during pregnancy on innate γδ T cells in the lung and thymus of newborn mice. Detailed time‐kinetic experiments showed that at birth, the murine lung T cell population was specifically dominated by IL17‐committed γδ T cells expressing an invariant Vγ6Vδ1 TCR. Single‐cell RNA‐sequencing showed that the biased IL17‐commitment of perinatal lung γδT cells is highly conserved between mice and humans. While maternal microbiota depletion with antibiotics tended to decrease the frequency of the lung Vγ6 T cells of the offspring at birth, the maternal administration of Lacticaseibacillus rhamnosus ( L.rhm .), but not of Bifidobacterium animalis subsp . lactis ( B.lac .), increased significantly their frequency, resulting in the augmentation of the IL17‐commitment of the mouse lung T cell compartment. Altogether, our data indicate that the maternal microbiota contributes to the shaping of IL17‐committed γδT cells in the lungs of newborns and that maternal administration of specific probiotic strains can enhance this process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy and Pharmaceutics, Université Libre de Bruxelles (ULB), Brussels, Belgium.
- Institute for Medical Immunology (IMI), Université Libre de Bruxelles (ULB), Gosselies, Belgium.
- ULB Center for Research in Immunology (U-CRI), Belgium.
- WELBIO Department, WEL Research Institute, Wavre, Belgium.
- Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université Catholique De Louvain, Brussels, Belgium.
ORCID-Profile: Moosa Rezwani, Maria Papadopoulou
Förderung
- WELBIO
- Fonds National de la Recherche Scientifique
- FNRS-CDR
- Service Public de Wallonie (SPW)
- FEDER Wallonia program
- Win-Win Wallonia program
- Fonds de la Recherche Scientifique
Zitieren
APA
Tafesse, Y., Köhler, A., Sanchez Sanchez, G., Rodrigues, P. B., Verce, M., Vitsos, P., Verdebout, I., Rezwani, M., Papadopoulou, M., Everard, A., Flamand, V., & Vermijlen, D. (2025). Maternal Administration of Probiotics Augments IL17‐Committed γδ T Cells in the Newborn Lung. European Journal of Immunology. https://doi.org/10.1002/eji.202451051
Vancouver
Tafesse Y, Köhler A, Sanchez Sanchez G, Rodrigues PB, Verce M, Vitsos P, et al. Maternal Administration of Probiotics Augments IL17‐Committed γδ T Cells in the Newborn Lung. European Journal of Immunology. 2025. doi:10.1002/eji.202451051
BibTeX
@article{Tafesse2025,
author = {Tafesse, Yohannes and Köhler, Arnaud and Sanchez Sanchez, Guillem and Rodrigues, Patricia Brito and Verce, Marko and Vitsos, Panagiotis and Verdebout, Isoline and Rezwani, Moosa and Papadopoulou, Maria and Everard, Amandine and Flamand, Véronique and Vermijlen, David},
title = {Maternal Administration of Probiotics Augments IL17‐Committed γδ T Cells in the Newborn Lung},
journal = {European Journal of Immunology},
year = {2025},
doi = {10.1002/eji.202451051}
}
EUVIMED